Supreme Court Curbs Public’s Right to Sue Pesticide Makers Over Cancer Warnings in Landmark Monsanto v. Durnell Decision

The Supreme Court has significantly altered the landscape of product liability law, eliminating a long-standing pathway for individuals to hold pesticide manufacturers accountable in state courts for failing to warn consumers about potential cancer risks. In a pivotal 7-2 ruling delivered last week in the case of Monsanto v. Durnell, the nation’s highest court determined that federal law preempts, or overrides, state-level "failure to warn" claims when the Environmental Protection Agency (EPA) has not mandated a cancer warning for a particular pesticide.

This decision marks a substantial victory for agrochemical giant Bayer, which acquired Monsanto in 2018, and has been embroiled in tens of thousands of lawsuits alleging that its flagship herbicide, Roundup, causes non-Hodgkin lymphoma. The ruling is expected to severely complicate, if not entirely block, a significant portion of the remaining litigation seeking compensation for cancer linked to Roundup and other pesticides, and it could deter similar future cases.

A Decisive Shift in Corporate Accountability

The core of the Supreme Court’s decision hinges on the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), the federal statute that governs the registration, labeling, and sale of pesticides in the United States. The majority opinion argued that if the EPA, under FIFRA, has reviewed and approved a pesticide’s label without requiring a cancer warning, then state law claims asserting a "failure to warn" are preempted. This interpretation effectively shields manufacturers from liability for not including warnings that the federal regulator deemed unnecessary.

For decades, consumer protection advocates and plaintiffs’ attorneys relied on state tort law to pursue claims against companies whose products allegedly caused harm, even if those products had received federal approval. The Durnell ruling narrows this avenue considerably, particularly in the highly regulated pesticide industry. The implications are profound, shifting the burden of demanding health warnings almost entirely to the EPA, a federal agency already facing scrutiny over its regulatory processes.

George Kimbrell, legal director at the Center for Food Safety (CFS), a leading nonprofit focused on food and agriculture issues, voiced strong disapproval of the decision. "Overturning decades of well-settled law, the Supreme Court eliminated one way the public held pesticide corporations accountable for their products’ harms," Kimbrell stated, reflecting the sentiments of a broad coalition of public interest stakeholders, including farmers, farmworkers, medical professionals, and conservationists, for whom CFS had filed an amicus brief in the case. While acknowledging the setback, Kimbrell affirmed the ongoing fight, emphasizing the heightened importance of EPA regulation and the potential for states and other governing bodies to pursue alternative roles in consumer protection. He described the ruling as a "clarion, galvanizing call to continued action," urging Americans to demand that their representatives prioritize public health over corporate profit margins.

The Genesis of the Roundup Litigation

The Monsanto v. Durnell case is a direct offshoot of the sprawling legal battle surrounding Roundup. Glyphosate, the active ingredient in Roundup, was introduced by Monsanto in the 1970s and quickly became the world’s most widely used herbicide due to its effectiveness and the advent of glyphosate-resistant crops. Its pervasive use, however, began to draw scrutiny regarding its potential health effects.

A pivotal moment arrived in March 2015 when the International Agency for Research on Cancer (IARC), a research arm of the World Health Organization (WHO), classified glyphosate as "probably carcinogenic to humans." This classification, though distinct from a definitive regulatory finding, ignited a torrent of lawsuits from individuals diagnosed with non-Hodgkin lymphoma, who alleged their cancer was caused by exposure to Roundup and that Monsanto failed to warn them of the risks.

The first bellwether trials proved devastating for Monsanto. In August 2018, a California jury awarded Dewayne "Lee" Johnson $289 million in damages (later reduced), finding that Roundup caused his cancer and that Monsanto acted with malice. Subsequent large verdicts, such as those in the Hardeman and Pilliod cases, where juries awarded hundreds of millions of dollars to plaintiffs, solidified the perception of significant legal exposure for the company. Bayer’s acquisition of Monsanto for $63 billion in June 2018 immediately plunged the German pharmaceutical and life sciences conglomerate into this unprecedented legal quagmire, leading to a dramatic drop in its stock value and intense pressure to resolve the litigation.

Impact on Ongoing and Future Lawsuits

The Supreme Court’s decision has created a bifurcated reality for the ongoing Roundup litigation. For Bayer, the ruling is cause for significant celebration. Carey Gillam, editor-in-chief at The New Lede and a veteran investigative journalist who has extensively covered Monsanto and its legal battles, noted the immediate positive market reaction. "Bayer is celebrating this ruling because the company believes that this will put an end to the lawsuits that are still outstanding," Gillam told Corporate Crime Reporter. "They believe that without the failure to warn claims, the lawsuits become much more difficult for the plaintiffs to prevail – and that plaintiffs are much more likely to settle and that people will be less likely to sue them in the future. They are very happy." Indeed, on the day of the ruling, Bayer’s stock saw a notable surge, climbing 17 percent as investors reacted favorably to the perceived reduction in legal risk.

However, the picture for plaintiffs and their attorneys is far more complex. While the "failure to warn" claim was a powerful and easily comprehensible argument for juries – "Here is the science, there is abundant scientific research out that shows a connection, that shows that at least it’s possible. You have the WHO classification. Why didn’t the company put that on the product, like a tobacco warning label? That resonated with jurors. I have interviewed several of them," Gillam explained – its elimination forces a strategic pivot.

Plaintiffs’ attorneys must now focus on alternative claims, primarily "design defect" and "negligence." These claims argue that the product itself was inherently dangerous or that the company acted negligently in its development or marketing, rather than simply failing to provide adequate warnings. While viable, these claims are often more technically complex and challenging to prove to a jury. "When you take that away and start arguing the technicalities of the design defect claim, it does whittle away at the ease with which juries understand these cases," Gillam observed. This increased complexity translates into higher costs for law firms, who invest millions in expert testimony and pretrial discovery. The potential for large punitive damages, which incentivized firms to take on these cases, may also diminish, making future litigation less attractive. "If you chip away at the large amount of money they can make, they will be a lot less likely to take these cases on. They are going to move on to something where they can make a lot more money," Gillam concluded.

The Landscape of Settlements and Class Actions

Before the Supreme Court’s ruling, the Roundup litigation had already seen extensive settlement activity. Of an estimated 170,000 claims, a vast majority have been resolved. Bayer has committed over $11 billion towards settlements and verdicts to date, with estimates suggesting 50,000 to 60,000 claims may still be outstanding. The company has also proposed an additional $7.25 billion to settle a class action lawsuit, hoping to draw a line under the entirety of the litigation.

The distinction between individual cases within a Multi-District Litigation (MDL) and a class action is crucial. The Roundup litigation was managed as an MDL, consolidating individual cases for pretrial matters like discovery and expert witness coordination under one judge, currently Judge Vince Chhabria in California. However, each case retains its individual identity and would return to its home court for trial. In contrast, a class action lumps all plaintiffs into a single group, with a unified settlement structure.

The proposed class action settlement for Roundup has been highly controversial. It was reportedly negotiated between Bayer and a select group of plaintiffs’ attorneys, many of whom were less involved in the initial, high-profile trials. Critics, including Judge Chhabria, have labeled it a "filthy" deal, arguing it disproportionately benefits the negotiating attorneys (who stood to receive approximately $600 million) while offering individual plaintiffs, many suffering from debilitating cancer, only a few thousand dollars each. This perceived inequity has fueled significant animosity among the broader plaintiffs’ bar, particularly those who led the charge in securing large verdicts.

The Supreme Court’s ruling now adds another layer of complexity to these settlement dynamics. Plaintiffs who previously opted out of the class action, hoping for a more substantial individual trial outcome based on "failure to warn" claims, must now re-evaluate their positions. The reduced strength of their legal arguments post-ruling may push more individuals towards accepting the class action settlement, despite its perceived shortcomings. Bayer has indicated that it might walk away from the proposed class action settlement if not enough plaintiffs agree to opt in, underscoring the strategic leverage the company has gained. A hearing scheduled for July 9 will shed more light on the opt-in/opt-out rates and the future of this particular settlement.

Legislative Response and Future Outlook

The Supreme Court’s decision has ignited calls for legislative action to restore the ability of individuals to sue pesticide manufacturers. Senator Cory Booker and Congresswoman Chellie Pingree have emerged as key figures in this effort. Pingree has already introduced legislation aimed at amending FIFRA to explicitly state that federal law does not preempt state "failure to warn" claims, effectively undoing the Supreme Court’s ruling. Senator Booker has explored similar amendments, possibly within the context of the Farm Bill.

However, passing such legislation faces formidable challenges. The agricultural industry, backed by powerful lobbyists, represents a significant political force in Washington, D.C. Overcoming their influence to pass legislation that increases corporate liability will be an uphill battle. Yet, a growing grassroots movement, often referred to as the "MAHA movement" (Make America Healthy Again) or "mad moms," is vowing to mobilize and make this a prominent issue in upcoming elections, signaling a potential for increased public pressure on lawmakers.

Beyond Roundup, the Durnell ruling sets a precedent that could impact other mass tort litigations involving federally regulated products. Carey Gillam highlighted the ongoing paraquat litigation, a weedkiller alleged to cause Parkinson’s disease, as a case already following a similar trajectory. "It’s smaller than the Roundup litigation. It’s newer than the Roundup litigation. But it is going down the same path," Gillam noted. In the paraquat MDL, Judge Nancy Rosenstengel is reportedly pressuring plaintiffs to accept a settlement that many plaintiffs’ lawyers deem "pitiful," even requiring those who refuse the offer to undergo additional scrutiny, such as depositions and meetings with a special master. This judicial behavior, aimed at inducing settlements, underscores the broader implications of the Supreme Court’s decision, which may further empower companies and judges to push for settlements rather than allowing individual cases to proceed to trial.

The Monsanto v. Durnell decision represents a significant legal and societal moment. It fundamentally redefines the balance of power between consumers, corporations, and federal regulators. While proponents argue it brings clarity to the regulatory landscape and prevents a patchwork of state-level warning requirements, critics contend it effectively immunizes companies from accountability for known or knowable product harms, placing an even greater, and perhaps undue, burden on the EPA to safeguard public health. The ensuing legal and political battles will determine the ultimate impact of this landmark ruling on consumer protection and corporate responsibility in the United States.